Login to Your Account

Clinic Roundup

Wednesday, September 11, 2013
Xenoport Inc., of Santa Clara, Calif., said it will advance XP23829, a fumaric acid ester compound that is a prodrug of monomethyl fumarate (MMF), in relapsing-remitting multiple sclerosis and/or psoriasis following positive preliminary results from two Phase I studies.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription